Article info
PostScript
Letter
Association between proton pump inhibitor use and mortality in patients with hepatocellular carcinoma receiving tyrosine kinase inhibitor
- Correspondence to Professor Chun-Ying Wu, Institute of Biomedical Informatics, School of Medicine, National Yang-Ming University, Taipei, Taiwan; dr.wu.taiwan{at}gmail.com
Citation
Association between proton pump inhibitor use and mortality in patients with hepatocellular carcinoma receiving tyrosine kinase inhibitor
Publication history
- Received May 22, 2020
- Revised August 23, 2020
- Accepted August 24, 2020
- First published September 9, 2020.
Online issue publication
July 12, 2021
Article Versions
- Previous version (9 September 2020).
- Previous version (21 December 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.